1. Home
  2. IIPR vs AGIO Comparison

IIPR vs AGIO Comparison

Compare IIPR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Industrial Properties Inc.

IIPR

Innovative Industrial Properties Inc.

HOLD

Current Price

$63.53

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$40.11

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIPR
AGIO
Founded
2016
2007
Country
United States
United States
Employees
23
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.2B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
IIPR
AGIO
Price
$63.53
$40.11
Analyst Decision
Hold
Buy
Analyst Count
3
8
Target Price
$45.00
$38.88
AVG Volume (30 Days)
301.7K
1.2M
Earning Date
05-04-2026
04-29-2026
Dividend Yield
14.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
$2.69
$76.75
Revenue Next Year
$3.80
$170.73
P/E Ratio
$10.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.58
$22.24
52 Week High
$64.84
$46.00

Technical Indicators

Market Signals
Indicator
IIPR
AGIO
Relative Strength Index (RSI) 60.66 64.07
Support Level $48.01 $39.31
Resistance Level N/A $43.81
Average True Range (ATR) 1.59 1.75
MACD 0.01 0.12
Stochastic Oscillator 71.81 54.62

Price Performance

Historical Comparison
IIPR
AGIO

About IIPR Innovative Industrial Properties Inc.

Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: